(Q35186873)

7 August 2017

1 reference

title

Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate (English)

1 reference

acute promyelocytic leukemia

7 August 2017

1 reference

1 reference

Ohno R

1

1 reference

7 August 2017

Asou N

series ordinal

2

1 reference

7 August 2017

Ohnishi K

series ordinal

3

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

17

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1454-1463

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403031

7 August 2017

exact match

0 references

cites work

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Acute promyelocytic leukemia: a curable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Retinoic acid resistance in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Retinoic acid syndrome: a problem of the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

PML a target of translocations in APL is a regulator of cellular senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Signaling revisited in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Acute promyelocytic leukaemia with t(11;17)(q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Annexin II and bleeding in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated 'sanctuary'?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403031

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403031

1 reference

Dimensions Publication ID

7 August 2017

1000323746

0 references

1 reference